Carl Zeiss Meditec/€AFX
1D1W1MYTD1Y5YMAX
Capital at risk
About Carl Zeiss Meditec
Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.
- Ticker
- €AFX
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 5,798
- Headquarters
- Jena, Germany
AFX Metrics
BasicAdvanced
€2.7B
21.85
€1.39
1.35
€0.55
1.81%
Price and volume
Market cap
€2.7B
Beta
1.35
52-week high
€48.38
52-week low
€22.66
Average daily volume
264K
Dividend rate
€0.55
Financial strength
Total debt to equity
0.276
Interest coverage (TTM)
6.47%
Profitability
EBITDA (TTM)
217.841
Gross margin (TTM)
51.56%
Net profit margin (TTM)
5.57%
Operating margin (TTM)
7.23%
Effective tax rate (TTM)
23.25%
Revenue per employee (TTM)
€380,000
Management effectiveness
Valuation
Price to earnings (TTM)
21.845
Price to revenue (TTM)
1.217
Price to book
1.26
Price to tangible book (TTM)
5.4
Dividend yield (TTM)
1.81%
Forward dividend yield
1.81%
Growth
Revenue change (TTM)
0.07%
Earnings per share change (TTM)
-18.69%
3-year revenue growth (CAGR)
1.60%
10-year revenue growth (CAGR)
7.18%
3-year earnings per share growth (CAGR)
-25.96%
10-year earnings per share growth (CAGR)
3.84%
10-year dividend per share growth (CAGR)
3.77%
What the Analysts think about AFX
Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.
Analyst projections of the future price of Carl Zeiss Meditec stock.
Bulls say / Bears say
Revenue stabilized on a currency-adjusted basis after nine months of fiscal 2025/26, and the company reported a slightly higher order backlog than at the end of fiscal 2024/25, suggesting potential support for future deliveries. (Carl Zeiss Meditec)
The Microsurgery segment grew 7.1% on a currency-adjusted basis in the first nine months, driven primarily by strong deliveries of neurosurgical operating microscopes and partially offsetting weakness in Ophthalmology. (Carl Zeiss Meditec)
Management has launched cost, structural and portfolio measures targeting more than €200 million of annual earnings improvement by fiscal 2028/29 versus fiscal 2025/26, creating material recovery potential if execution is successful. (Carl Zeiss Meditec)
Adjusted EBITA fell to €124.5 million from €177.0 million in the first nine months of fiscal 2025/26, while the adjusted EBITA margin declined to 8.0% from 11.1%; EPS also decreased to €0.80 from €1.02. (Carl Zeiss Meditec)
Ophthalmology revenue declined 2.9% on a currency-adjusted basis, with China affected by the withdrawal of a bifocal intraocular lens from a volume-based procurement tender and weaker refractive-laser demand. (Carl Zeiss Meditec)
APAC revenue fell 7.6% on a currency-adjusted basis, while gross margin contracted to 51.0% from 52.7%; profitability was also pressured by acquisition-related impairments, legal disputes and restructuring costs. (Carl Zeiss Meditec)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
AFX Financial Performance
Revenues and expenses
AFX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AFX
AllEURGBPUSD
Fund name | Fund size | €AFX weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 0.86% |
iShares Ageing Population€AGED | €822M | 0.11% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
Amundi STOXX Europe 600€MEUD | €7.6B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.